Clinical Data Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease PharmaTimesSubcutaneous delivery shows IVlevel efficacy in moderate to severe TEDClinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) PharmaTimes Subcutaneous delivery shows IVlevel efficacy in moderate to severe TED Clinical DataOphthalmologyRead full story Post navigation Previous: FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing ChangesNext: Kennedy changes vaccine panel charter after legal setback Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
